Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-05-19

Clinical Trial Update: AZD7325 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD) [Phase 2]

View source ↗

Summary

A Phase 2 proof-of-concept trial of AZD7325 in generalized anxiety disorder has completed, with results posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AZD7325 (AZD7325)

Snippet

Sponsor: AstraZeneca | Conditions: Anxiety Disorders | Phase 2 | Status: COMPLETED | Results posted: 2011-05-19